Y Naraoka1, T Yamaguchi2, A Hu2, K Akimoto1, H Kobayashi1,2. 1. Juntendo University, Graduate School of Medicine, Department of Hospital Administration, Tokyo, Japan. 2. Juntendo University, Graduate School of Medicine, Center for Advanced Kampo Medicine and Clinical Research, Tokyo, Japan.
Abstract
PURPOSE: Short chain fatty acids (SCFAs) play a major regulatory role in adipocyte function and metabolism. The aim of this study was to investigate the effects of SCFAs on adiponectin and leptin expression in adipocytes, and also to determine whether the effects of SCFA treatment in visceral adipocytes obtained from healthy subjects are different relative to the effects in adipocytes from patients with type 2 diabetes. MATERIALS AND METHODS: Human pericardiac preadipocytes and human pericardiac preadipocytes type 2 diabetes were differentiated into adipocytes for 21 days in 48-well plates. After differentiation, two kinds of mature adipocytes, human pericardiac adipocytes (HPAd) and human pericardiac adipocytes-type 2 diabetes (HPAd-T2D) were incubated with or without 1 mM of acetic acid (AA), butyrate acid (BA), and propionic acid (PA). After 48 hours of incubation, intracellular lipid accumulation was measured using oil red staining. In addition, mRNA levels of adiponectin, leptin and Peroxisome Proliferator-Activated Receptor γ (PPARγ) were determined by Real-Time PCR system. RESULTS: In HPAd, SCFA supplementation did not inhibit lipid accumulation. By contrast, both AA (p<0.01) and PA (p<0.01) significantly inhibited lipid accumulation in HPAd-T2D. Regarding mRNA levels of adiponectin, no significant changes were found in HPAd, while all three types of SCFAs significantly increased (p<0.05) adiponectin expression in HPAd-T2D. Leptin mRNA expression levels were significantly increased by treatment with all three types of SCFAs in both HPAd (p<0.05) and HPAd-T2D (p<0.05). CONCLUSION: SCFAs inhibited lipid droplet accumulation and increased mRNA expression of adiponectin and leptin in T2D-derived adipocytes.
PURPOSE: Short chain fatty acids (SCFAs) play a major regulatory role in adipocyte function and metabolism. The aim of this study was to investigate the effects of SCFAs on adiponectin and leptin expression in adipocytes, and also to determine whether the effects of SCFA treatment in visceral adipocytes obtained from healthy subjects are different relative to the effects in adipocytes from patients with type 2 diabetes. MATERIALS AND METHODS: Human pericardiac preadipocytes and human pericardiac preadipocytes type 2 diabetes were differentiated into adipocytes for 21 days in 48-well plates. After differentiation, two kinds of mature adipocytes, human pericardiac adipocytes (HPAd) and human pericardiac adipocytes-type 2 diabetes (HPAd-T2D) were incubated with or without 1 mM of acetic acid (AA), butyrate acid (BA), and propionic acid (PA). After 48 hours of incubation, intracellular lipid accumulation was measured using oil red staining. In addition, mRNA levels of adiponectin, leptin and Peroxisome Proliferator-Activated Receptor γ (PPARγ) were determined by Real-Time PCR system. RESULTS: In HPAd, SCFA supplementation did not inhibit lipid accumulation. By contrast, both AA (p<0.01) and PA (p<0.01) significantly inhibited lipid accumulation in HPAd-T2D. Regarding mRNA levels of adiponectin, no significant changes were found in HPAd, while all three types of SCFAs significantly increased (p<0.05) adiponectin expression in HPAd-T2D. Leptin mRNA expression levels were significantly increased by treatment with all three types of SCFAs in both HPAd (p<0.05) and HPAd-T2D (p<0.05). CONCLUSION: SCFAs inhibited lipid droplet accumulation and increased mRNA expression of adiponectin and leptin in T2D-derived adipocytes.
Authors: Andrew J Brown; Susan M Goldsworthy; Ashley A Barnes; Michelle M Eilert; Lili Tcheang; Dion Daniels; Alison I Muir; Mark J Wigglesworth; Ian Kinghorn; Neil J Fraser; Nicholas B Pike; Jay C Strum; Klaudia M Steplewski; Paul R Murdock; Julie C Holder; Fiona H Marshall; Philip G Szekeres; Shelagh Wilson; Diane M Ignar; Steve M Foord; Alan Wise; Simon J Dowell Journal: J Biol Chem Date: 2002-12-19 Impact factor: 5.157
Authors: Andrea R Nawrocki; Michael W Rajala; Eva Tomas; Utpal B Pajvani; Asish K Saha; Myrna E Trumbauer; Zhen Pang; Airu S Chen; Neil B Ruderman; Howard Chen; Luciano Rossetti; Philipp E Scherer Journal: J Biol Chem Date: 2005-12-02 Impact factor: 5.157
Authors: Myeong Jin Yoon; Gha Young Lee; Jun-Jae Chung; Young Ho Ahn; Seung Hwan Hong; Jae Bum Kim Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki Journal: Nat Med Date: 2001-08 Impact factor: 53.440
Authors: Yumei Xiong; Norimasa Miyamoto; Kenji Shibata; Mark A Valasek; Toshiyuki Motoike; Rafal M Kedzierski; Masashi Yanagisawa Journal: Proc Natl Acad Sci U S A Date: 2004-01-13 Impact factor: 11.205
Authors: Huiqing Shi; Rob Ter Horst; Suzanne Nielen; Mirjam Bloemendaal; Martin Jaeger; Irma Joosten; Hans Koenen; Leo A B Joosten; Lizanne J S Schweren; Alejandro Arias Vasquez; Mihai G Netea; Jan Buitelaar Journal: Sci Rep Date: 2022-03-25 Impact factor: 4.379